Sun Pharma Earmarks $100 Mn Spend In FY26

New Delhi: Sun Pharmaceutical Industries has lined up a $100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi.

The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company’s speciality (patented products) business for the future. “For the current year, we are looking to invest approximately $100 million additionally on the commercialisation of new speciality products,” Shanghvi told analysts in a call.

The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company’s global speciality sales rose 17.1 per cent to $1,216 million. In the January-March quarter of FY25, the sales were up 8.6 per cent to $295 million.